Loading...
Real-Life real-life barriers to diagnosis of early mycosis fungoides: an international expert panel discussionBarriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
Hodak, E. Geskin, L. Guenova, E. Ortiz-Romero, P. L. Willemze, R. Zheng, J. Cowan, Richard A Foss, F. Mangas, C. Querfeld, C.
Hodak, E.
Geskin, L.
Guenova, E.
Ortiz-Romero, P. L.
Willemze, R.
Zheng, J.
Cowan, Richard A
Foss, F.
Mangas, C.
Querfeld, C.
Citations
Altmetric:
Abstract
Mycosis fungoides (MF) is a rare, primary cutaneous T-cell lymphoma that is challenging to diagnose due to its heterogeneous clinical presentation and complex histology. The subtlety of the initial clinical appearance of MF can result in diagnostic delays and hesitancy to refer suspected cases to specialist clinics. An unmet need remains for greater awareness and education. Therefore, an international expert panel of dermatologists, oncologists, hematologists, and dermatopathologists convened to discuss and identify barriers to early and accurate MF diagnosis that could guide clinicians toward making a correct diagnosis. Confirmation of MF requires accurate assessment of symptoms and clinical signs, and subsequent correlation with dermatopathological findings. This review summarizes the expert panel's guidance, based on the literature and real-life experience, for dermatologists to help include MF in their list of differential diagnoses, along with simple clinical and histopathologic checklists that may help clinicians to suspect and identify potential MF lesions and reduce diagnostic delays.
Description
Date
2022
Publisher
Collections
Files
Keywords
Type
Article
Citation
Hodak E, Geskin L, Guenova E, Ortiz-Romero PL, Willemze R, Zheng J, et al. Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion. Am J Clin Dermatol. 2022 Nov 18:1-10. PubMed PMID: 36399227. Pubmed Central PMCID: PMC9673193 Diseases and Takeda, and speakers’ bureaus for Helsinn, Rafa and Takeda. LG has received research support from Helsinn Group, J&J, Mallinckrodt, Kyowa Kirin, Soligenix, Innate, miRagen, Galderma, Merck, BMS and Stratpharma; and has served on speakers’ bureaus for Helsinn Group and J&J, and scientific advisory boards for Helsinn Group, J&J, Mallinckrodt, Sanofi, Regeneron and Kyowa Kirin. EG has been a member of the scientific advisory board of Scailyte AG and has received grants and personal fees from Helsinn Healthcare, Kyowa Hakko Kirin and Takeda; and personal fees from Mallinckrodt Pharmaceuticals, Recordati, Novartis and Sanofi. PLO-R has served on advisory boards for Recordati Rare Diseases, Helsinn, 4SC, Innate Pharma, Kyowa Pharma Chemical Co., Takeda, miRagen Therapeutics and Actelion. RW has been a member of the scientific advisory board of Helsinn. JZ declares no conflicts of interest. RC has served as a consultant for Kyowa Kirin and as a member of the scientific advisory board for Helsinn Healthcare. FF has served as a consultant for Kyowa and Mallinkrodt. CM has served on advisory boards for Novartis, Helsinn, Bristol Myers Squibb, Sanofi and Pierre Fabre. CQ has served on advisory board/scientific committees for Helsinn, Bioniz, miRagen, Trillium and Kyowa Kirin; and has received research funding from Celgene. Epub 2022/11/19. eng.